Showing 1161-1170 of 20877 results for "".
- CDC Reports Interim 2025-26 Influenza Vaccine Effectivenesshttps://reachmd.com/news/cdc-reports-interim-2025-26-influenza-vaccine-effectiveness/2486778/Key Takeaways Vaccination was associated with reduced risk for influenza-associated outpatient visits and hospitalization, with higher overall estimates in children and adolescents than in adults. Reported protection included influenza A(H3N2) and infl
- POINTER Imaging Study Links Brain Biomarkers, Cognitive Benefithttps://reachmd.com/news/pointer-imaging-study-links-brain-biomarkers-cognitive-benefit/2486780/Key Takeaways No overall intervention-group differences were observed in longitudinal cognitive or imaging outcomes. Aβ status and Aβ accumulation were not associated with intervention-group differences and did not moderate them. In the struct
- Atacicept Reduced Proteinuria in Phase 3 IgA Nephropathy Trialhttps://reachmd.com/news/atacicept-reduced-proteinuria-in-phase-3-iga-nephropathy-trial/2486785/Key Takeaways At week 36, proteinuria declined more with atacicept than with placebo in the prespecified interim phase 3 readout. ORIGIN 3 is an ongoing randomized, double-blind, placebo-controlled phase 3 trial with 1:1 assignment and weekly subcutane
- Acute Ischemic Stroke Prognosis Improved by LLMhttps://reachmd.com/news/stroke-outcome-prediction-llm/2486681/At the AAN 2026 conference, investigators presented a reasoning-enhanced large language
- CORAL Trial: Oral Nalbuphine Reduces Cough in IPFhttps://reachmd.com/news/oral-nalbuphine-cough-ipf-coral-trial/2486679/Key Takeaways In the CORAL trial, three nalbuphine ER doses were associated with greater objective cough reduction than placebo at week 6. Patient-reported cough frequency improved versus placebo in the 54-mg and 108-mg groups, while the 27-mg group di
- GBM AGILE Phase II/III Bayesian Randomized Platform Trialhttps://reachmd.com/news/gbm-agile-phase-iiiii-bayesian-randomized-platform-trial/2486655/Key Takeaways In GBM AGILE, regorafenib did not improve overall survival versus control in either newly diagnosed unmethylated or recurrent glioblastoma and enrollment stopped early for limited efficacy. The trial used a phase II/III Bayesian adaptive
- Insurance And Employment After Medicaid Expansion Work Ruleshttps://reachmd.com/news/insurance-and-employment-after-medicaid-expansion-work-rules/2486663/Researchers conducted a quasi-experimental difference-in-differences study to evaluate how Medicaid expansion with work requirements affected ins
- Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectivenesshttps://reachmd.com/news/interim-estimates-of-2025-26-seasonal-influenza-vaccine-effectiveness/2486668/Key Takeaways In interim estimates, vaccine effectiveness against influenza-associated outpatient visits was 38%–41% in children and adolescents and 22%–34% in adults; effectiveness against influenza-associated hospitalization was 41% and 30%, respectively.
- Ravulizumab in IgA Nephropathy: Phase 2 Trial Readouthttps://reachmd.com/news/ravulizumab-in-iga-nephropathy-phase-2-trial-readout/2486671/Key Takeaways During the randomized period, ravulizumab was associated with a greater reduction in proteinuria than placebo at week 26 (−41.9% vs −16.8%; treatment effect 30.1%; P = 0.005). Investigators reported a trend toward eGFR stabilization (leas
- Peanut Oral Immunotherapy Value Assessed In Childrenhttps://reachmd.com/news/peanut-oral-immunotherapy-value-assessed-in-children/2486660/Key Takeaways This economic evaluation compared probiotic and peanut oral immunotherapy (PPOIT), peanut oral immunotherapy (OIT), and no treatment for children with peanut allergy. Both PPOIT and OIT were cost-effective compared with no treatment when